Boston, Mass., May 12, 2016 – The Institute for Clinical and Economic Review (ICER) has announced the appointment of its first Chief Medical Officer. David Rind, MD, MSc is a primary care physician with expertise in evidence-based medicine and particular experience in reviewing the evidence for diagnostic and therapeutic interventions. In his role, Dr. Rind is responsible for leading teams conducting analyses and critical appraisals of medical evidence across a wide range of clinical interventions. Dr. Rind also holds a leadership role at ICER, helping to guide high-level policy discussions of the interpretation and application of evidence.
“We are thrilled to have Dr. Rind join the ICER team as Chief Medical Officer,” noted Steven D. Pearson, MD, MSc, President of ICER. “His experience and expertise will serve to elevate the level of work ICER produces. We are confident that Dr. Rind will have a meaningful impact both on our reviews and on the application of our work.”
Before coming to ICER, Dr. Rind worked at UpToDate for 13 years where he held senior positions within the editorial group. Dr. Rind began work at UpToDate in 2003, when he became the primary care Deputy Editor. Dr. Rind was central to restructuring how UpToDate presents recommendations and led their work collaborating with the Grading Recommendations Assessment, Development, and Evaluation (GRADE) Working Group, introducing graded recommendations into UpToDate in 2005. Dr. Rind remains a member of GRADE. At UpToDate, Dr. Rind was also responsible for training physician editors in clinical epidemiology, biostatistics, and evidence-based medicine. His roles at UpToDate, where he worked until 2016, included Senior Deputy Editor, Director of Evidence-Based Medicine, Co-Executive Editor, and the Vice-President of Editorial and Evidence-Based Medicine.
Dr. Rind received a BA in chemistry from Yale University and his MD from the University of Rochester. He completed his residency in internal medicine at the University of Massachusetts Medical Center and then did a joint fellowship in general internal medicine and clinical computing at Beth Israel Hospital and Harvard Medical School. He received a Master of Science in health policy and management from the Harvard School of Public Health.
ICER is continuing to expand its team. For a full listing of open positions, including roles in health technology assessment, program coordination, and administration, please visit ICER’s website.
The Institute for Clinical and Economic Review (ICER
) is an independent non-profit research institute that produces reports analyzing the evidence on the effectiveness and value of drugs and other medical services. ICER’s reports include evidence-based calculations of prices for new drugs that accurately reflect the degree of improvement expected in long-term patient outcomes, while also highlighting price levels that might contribute to unaffordable short-term cost growth for the overall health care system.
ICER’s reports incorporate extensive input from all stakeholders and are the subject of public hearings through three core programs: the California Technology Assessment Forum (CTAF
), the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC
) and the New England Comparative Effectiveness Public Advisory Council (New England CEPAC
). These independent panels review ICER’s reports at public meetings to deliberate on the evidence and develop recommendations for how patients, clinicians, insurers, and policymakers can improve the quality and value of health care. For more information about ICER, please visit ICER’s website